EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Existing Drugs Targeting Genes of Hereditary Pain Syndromes as Candidates for Analgesic Repurposing: An AI-Facilitated Computational Knowledge Discovery Analysis

Jörn Lötsch, André Himmelspach, Dario Kringel

Pharmaceuticals · 20.11.2026 · 19 (11) · 1854

DOI: 10.3390/ph19111854 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 20.11.2026. Verfasst von Jörn Lötsch und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Over the last few decades, hereditary syndromes with extreme pain phenotypes have guided the discovery of analgesic drugs. We hypothesized that genes of hereditary syndromes with altered pain perception, not necessarily the extreme phenotypes grouped as hereditary sensory and autonomic neuropathies, could also point to existing drugs with unrecognized analgesic properties via known interactions with syndrome-relevant gene products.

Methods

Phenotypes with altered pain mentions were retrieved from the Online Mendelian Inheritance in Man (OMIM) database, and their genes were linked to targets of approved and investigational drugs in DrugBank. The 3662 PubMed records for the 169 drugs without pain annotation, of which 3237 remained after rule-based exclusions, were screened on title and abstract, assisted by a large language model with human verification of positive and inconclusive findings.

Results

Eighty qualifying phenotypes were found, annotated with 81 genes, of which 22 were targets of 201 existing drugs. DrugBank mentioned pain or analgesia for 32 drugs (15.9%). Of the other 169 drugs, 51 (30.2%) had published reports of an analgesic or antinociceptive effect without explicit database annotation, including oxcarbazepine, lacosamide, and memantine. Published evidence included human data for 15 drugs and only preclinical data for 36 drugs, while for 73 drugs no record was retrieved.

Conclusions

The main result of this analysis is a list of 169 drugs that target these genes but are not labeled as analgesics. Given the limited options for pain therapy, this AI-assisted, knowledge-based framework seems a feasible way to select candidates for expanding the class of analgesics through drug repurposing.

Zitieren

APA

Lötsch, J., Himmelspach, A., & Kringel, D. (2026). Existing Drugs Targeting Genes of Hereditary Pain Syndromes as Candidates for Analgesic Repurposing: An AI-Facilitated Computational Knowledge Discovery Analysis. Pharmaceuticals, 19(11), 1854. https://doi.org/10.3390/ph19111854

Vancouver

Lötsch J, Himmelspach A, Kringel D. Existing Drugs Targeting Genes of Hereditary Pain Syndromes as Candidates for Analgesic Repurposing: An AI-Facilitated Computational Knowledge Discovery Analysis. Pharmaceuticals. 2026;19(11):1854. doi:10.3390/ph19111854

BibTeX
@article{Ltsch2026,
  author = {Lötsch, Jörn and Himmelspach, André and Kringel, Dario},
  title = {Existing Drugs Targeting Genes of Hereditary Pain Syndromes as Candidates for Analgesic Repurposing: An AI-Facilitated Computational Knowledge Discovery Analysis},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {11},
  pages = {1854},
  doi = {10.3390/ph19111854}
}
Kostenlos starten →